236 related articles for article (PubMed ID: 30939771)
21. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
[TBL] [Abstract][Full Text] [Related]
22. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
[TBL] [Abstract][Full Text] [Related]
23. Potential anti-cholinesterase and β-site amyloid precursor protein cleaving enzyme 1 inhibitory activities of cornuside and gallotannins from Cornus officinalis fruits.
Bhakta HK; Park CH; Yokozawa T; Tanaka T; Jung HA; Choi JS
Arch Pharm Res; 2017 Jul; 40(7):836-853. PubMed ID: 28589255
[TBL] [Abstract][Full Text] [Related]
24. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors.
Pan Y; Wang Y; Bryant SH
J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
Masaki S; Kii I; Sumida Y; Kato-Sumida T; Ogawa Y; Ito N; Nakamura M; Sonamoto R; Kataoka N; Hosoya T; Hagiwara M
Bioorg Med Chem; 2015 Aug; 23(15):4434-4441. PubMed ID: 26145823
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease.
Meena P; Nemaysh V; Khatri M; Manral A; Luthra PM; Tiwari M
Bioorg Med Chem; 2015 Mar; 23(5):1135-48. PubMed ID: 25624107
[TBL] [Abstract][Full Text] [Related]
27. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
[TBL] [Abstract][Full Text] [Related]
28. Rational design of central selective acetylcholinesterase inhibitors by means of a "bio-oxidisable prodrug" strategy.
Bohn P; Le Fur N; Hagues G; Costentin J; Torquet N; Papamicaël C; Marsais F; Levacher V
Org Biomol Chem; 2009 Jun; 7(12):2612-8. PubMed ID: 19503937
[TBL] [Abstract][Full Text] [Related]
29. Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
Hameed A; Zehra ST; Shah SJ; Khan KM; Alharthy RD; Furtmann N; Bajorath J; Tahir MN; Iqbal J
Chem Biol Drug Des; 2015 Nov; 86(5):1115-20. PubMed ID: 25951978
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and evaluation of 7H-thiazolo-[3,2-b]-1,2,4-triazin-7-one derivatives as dual binding site acetylcholinesterase inhibitors.
Liu S; Shang R; Shi L; Zhou R; He J; Wan DC
Chem Biol Drug Des; 2014 Aug; 84(2):169-74. PubMed ID: 24890706
[TBL] [Abstract][Full Text] [Related]
31. Novel aromatic-polyamine conjugates as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase.
Hong C; Luo W; Yao D; Su YB; Zhang X; Tian RG; Wang CJ
Bioorg Med Chem; 2014 Jun; 22(12):3213-9. PubMed ID: 24794747
[TBL] [Abstract][Full Text] [Related]
32. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
[TBL] [Abstract][Full Text] [Related]
33. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Acetylcholinesterase (AChE): A Potential Therapeutic Target to Treat Alzheimer's Disease.
Li Y; Zhang XX; Jiang LJ; Yuan L; Cao TT; Li X; Dong L; Li Y; Yin SF
Chem Biol Drug Des; 2015 Oct; 86(4):776-82. PubMed ID: 25736722
[TBL] [Abstract][Full Text] [Related]
35. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
Ogawa Y; Nonaka Y; Goto T; Ohnishi E; Hiramatsu T; Kii I; Yoshida M; Ikura T; Onogi H; Shibuya H; Hosoya T; Ito N; Hagiwara M
Nat Commun; 2010 Oct; 1():86. PubMed ID: 20981014
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.
Pang X; Fu H; Yang S; Wang L; Liu AL; Wu S; Du GH
Molecules; 2017 Jul; 22(8):. PubMed ID: 28933746
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
Ghobadian R; Nadri H; Moradi A; Bukhari SNA; Mahdavi M; Asadi M; Akbarzadeh T; Khaleghzadeh-Ahangar H; Sharifzadeh M; Amini M
Bioorg Med Chem; 2018 Sep; 26(17):4952-4962. PubMed ID: 30190181
[TBL] [Abstract][Full Text] [Related]
38. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
Lan JS; Ding Y; Liu Y; Kang P; Hou JW; Zhang XY; Xie SS; Zhang T
Eur J Med Chem; 2017 Oct; 139():48-59. PubMed ID: 28797883
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer's Disease.
Wu W; Liang X; Xie G; Chen L; Liu W; Luo G; Zhang P; Yu L; Zheng X; Ji H; Zhang C; Yi W
Molecules; 2018 Oct; 23(10):. PubMed ID: 30301153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
